Centrient Announces Phil Wieland Appointed Supervisory Board Chairman
Centrient Pharmaceuticals,* a leading global business-to-business supplier of sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals, is pleased to announce the appointment of Phil Wieland as the new Chairman of its Supervisory Board of Directors, effective 20 January 2025.
“I am excited to join Centrient’s Supervisory Board and support Centrient during this next phase of its development,” said Phil Wieland, incoming Supervisory Board Chairman. “Centrient has grown over the years into a true leader in delivering life-saving, foundational medicines to the global healthcare system. With its diversified portfolio of intermediates, APIs, and FDFs covering beta-lactam antibiotics, next-generation statins, and antifungals, Centrient is uniquely positioned for further growth. I look forward to supporting the Executive Committee in executing Centrient’s strategy.
“Furthermore, I am especially proud to be part of an enterprise so deeply committed to addressing Anti-Microbial Resistance, one of the biggest challenges to global health,” added Wieland.
Phil Wieland brings extensive expertise in strategic leadership, finance, and operations, with a proven track record as a former CEO of Diversey, a global leader in the hygiene and cleaning industry, and other senior roles as CEO and CFO in the services sector.
Centrient’s Chief Executive Officer, Rex Clements, expressed his enthusiasm for Wieland’s appointment: “I am looking forward to Phil joining Centrient and contributing his diverse experience. We are at an exciting stage of our development, and Phil’s unparalleled expertise will be instrumental in guiding our growth trajectory.
“I would also like to extend my heartfelt thanks to Benjamin Kunstler for his leadership and his continued support as a valued member of our Supervisory Board. With Phil’s appointment, Centrient is even better positioned to continue delivering on its mission to provide sustainable solutions and life-saving medicines.”
Centrient Pharmaceuticals continues to expand its global footprint and capitalise on its position as the only Western-based global player of scale with world-leading biosynthetic and proprietary enzymatic technologies.
About Centrient Pharmaceuticals
Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. We are a pharmaceutical company with a clear Purpose: to improve lives through innovative and sustainable manufacturing of medicines - saving the lives of millions of people around the world annually. Regarding our portfolio, we produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as finished dosage forms (FDFs). Centrient Pharmaceuticals is a Board Member of the AMR Industry Alliance and a long-time advocate for industry responsibility in manufacturing.
For more information, please visit www.centrient.com, www.linkedin.com/company/centrient or contact Centrient Pharmaceuticals Global Communications and ESG Director, Neil Moorhouse. E-Mail: neil.moorhouse@centrient.com.
(*) “Centrient Pharmaceuticals”, “Centrient” in this content are sometimes used for convenience where references are made to Centrient International Pharmaceuticals B.V, and or one or more of its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Centrient Pharmaceuticals International B.V. and or one or more of its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. “Subsidiaries”, “Centrient subsidiaries” and “Centrient companies” as used in this content refer to entities over which Centrient Pharmaceuticals International B.V. either directly or indirectly has control. The term “Centrient interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Centrient Pharmaceuticals International B.V. in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.
